Abstract
Objective
To develop and validate a population pharmacokinetic model for gentamicin in horses, using retrospective clinical data.
Animals
62 horses that had been treated IV with multiple doses of gentamicin at our veterinary teaching hospital between 1987 and 1996.
Procedure
46 horses were assigned to the study group, and 16 to the validation group. Detailed history of dosage, sample collection times, and selected pathophysiologic variables were recorded for each patient. Samples were analyzed by use of a fluorescence polarization immunoassay method. Pharm-acostatistical analysis was conducted, using computer software. The predictive model correlates pharmacokinetic parameters to concomitant pathophysiologic variables and estimates the inter- and intraindividual variability in disposition.
Results
A two-compartment model best described the data. Clearance (Cl) was linearly correlated to body weight and serum creatinine concentration. Volume of the central compartment (Vdc) was linearly related to body weight. Interindividual coefficients of variability for Cl and Vdc were 24 and 16%, respectively. The residual variability (intraindividual) was 13%; mean prediction error percent (bias) was 2%; and mean absolute prediction error percent (precision) was 29%.
Conclusions
Population pharmacokinetic analysis allows study of the basic features of gentamicin disposition in horses with sparse data per individual. A considerable proportion of the pharmacokinetic variability of gentamicin in our study population was explained by differences in body weight and serum creatinine concentration.
Clinical Relevance
Population pharmacokinetics can be used to design first-dosage regimens according to the clinical characteristics of individual animals. Population pharmacokinetic models could also be included in Bayesian forecasting strategies to improve plasma concentration predictions in individual patients. (Am J Vet Res 1998;59:1589-1598)
